Trials / Terminated
TerminatedNCT02626702
Immune Modulators and IVF
Immune Modulators in Women Undergoing IVF----a Prospective Study
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (actual)
- Sponsor
- Weill Medical College of Cornell University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 44 Years
- Healthy volunteers
- Not accepted
Summary
Exploring the immune mediators of early pregnancy prospectively may help to identify new early interventions that will increase the likelihood of success and help women make informed decisions regarding their pregnancies.
Detailed description
Sera will be obtained from 500 women undergoing IVF at five time periods: cycle Day 2, post HCG, Day 24, Day 28, and/or Day 35.Aliquots of sera will be tested by commercial ELISA kits for concentrations of immune modulators suggestive to be predictive of IVF outcome, such as cytokines (interleukins, tumor necrosis factor, and interferon), neurotrophins (BDNF), protease inhibitors (HE4) and insulin-like growth factors (IGF-1, IGF-2, IGFBP). The results will be correlated with IVF outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Observational | Excess blood from subjects will be analyzed to explore the relationship between Immune Modulators and IVF outcomes. |
Timeline
- Start date
- 2015-07-31
- Primary completion
- 2019-08-09
- Completion
- 2019-08-31
- First posted
- 2015-12-10
- Last updated
- 2019-09-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02626702. Inclusion in this directory is not an endorsement.